Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC65H82N6O10 |
InChIKeyURDKILVGEVSNPJ-JCMBZIHHSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | JP | 02 Mar 2017 | |
Neoplasms | Preclinical | JP | 02 Mar 2017 |